EW — Edwards Lifesciences Share Price
0.000.00%
Last trade - 00:00- $45.05bn
- $41.81bn
- $5.44bn
- 93
- 24
- 83
- 74
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 29.22 | ||
| PEG Ratio (f) | 4.2 | ||
| EPS Growth (f) | 7.48% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.45 | ||
| Price to Tang. Book | 6.28 | ||
| Price to Free Cashflow | 72.29 | ||
| Price to Sales | 8.13 | ||
| EV to EBITDA | 26.66 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.27% | ||
| Return on Equity | 16.73% | ||
| Operating Margin | 25.77% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4,386.3 | 5,232.5 | 4,464 | 5,010 | 5,439.5 | 5,906.57 | 6,470.61 | 4.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +4.98 | +28.25 | -7.78 | +3.65 | +4.5 | +3.1 | +11.56 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Directors
- Michael Mussallem CHM (68)
- Scott Ullem CFO (55)
- Jean-Luc Lemercier CEX (64)
- Donald Bobo VPR (59)
- Daveen Chopra VPR (42)
- Catherine Szyman VPR (54)
- Huimin Wang VPR (64)
- Larry Wood VPR (55)
- Martha Marsh LED (72)
- Kieran Gallahue IND (57)
- Leslie Heisz IND (60)
- Paul LaViolette IND (63)
- Steven Loranger IND (69)
- Ramona Sequeira IND (55)
- Nicholas Valeriani IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 10th, 1999
- Public Since
- March 27th, 2000
- No. of Shareholders
- 7,197
- No. of Employees
- 15,800
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 586,600,000
- Address
- One Edwards Way, IRVINE, 92614
- Web
- https://www.edwards.com
- Phone
- +1 9492502500
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for EW
Q3 2025 Edwards Lifesciences Corp Earnings Release
Similar to EW
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
What is the Edwards Lifesciences share price?
As of Today at 20:22 UTC, shares in Edwards Lifesciences are trading at $76.79. This share price information is delayed by 15 minutes.
How has the Edwards Lifesciences share price performed this year?
Shares in Edwards Lifesciences last closed at $76.79 and the price had moved by -15.69% over the past 365 days. In terms of relative price strength the Edwards Lifesciences share price has underperformed the S&P500 Index by -24.63% over the past year.
What are the analyst and broker recommendations for Edwards Lifesciences?
The overall consensus recommendation for Edwards Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Edwards Lifesciences dividend yield?
Edwards Lifesciences does not currently pay a dividend.
Does Edwards Lifesciences pay a dividend?
Edwards Lifesciences does not currently pay a dividend.
When does Edwards Lifesciences next pay dividends?
Edwards Lifesciences does not currently pay a dividend.
How do I buy Edwards Lifesciences shares?
To buy shares in Edwards Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Edwards Lifesciences?
As of the previous close price of $76.79, shares in Edwards Lifesciences had a market capitalisation of $45.05bn.
Where are Edwards Lifesciences shares listed?
Here are the trading details for Edwards Lifesciences:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: EW
What kind of share is Edwards Lifesciences?
Based on an overall assessment of its quality, value and momentum Edwards Lifesciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Edwards Lifesciences share price forecast for 2025?
The analyst consensus target price for shares in Edwards Lifesciences is $81.28. That is 5.85% above the last closing price of $76.79.
Analysts covering Edwards Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of $2.48 for the next financial year.
Find out moreWhat is the trend in the Edwards Lifesciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Edwards Lifesciences. Over the past six months, its share price has underperformed the S&P500 Index by -0.31%.
As of the last closing price of $76.79, shares in Edwards Lifesciences were trading +6.92% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Edwards Lifesciences PE Ratio?
The Edwards Lifesciences PE ratio based on its reported earnings over the past 12 months is 29.22. The shares last closed at $76.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Edwards Lifesciences?
Edwards Lifesciences' management team is headed by:
- Michael Mussallem - CHM
- Scott Ullem - CFO
- Jean-Luc Lemercier - CEX
- Donald Bobo - VPR
- Daveen Chopra - VPR
- Catherine Szyman - VPR
- Huimin Wang - VPR
- Larry Wood - VPR
- Martha Marsh - LED
- Kieran Gallahue - IND
- Leslie Heisz - IND
- Paul LaViolette - IND
- Steven Loranger - IND
- Ramona Sequeira - IND
- Nicholas Valeriani - IND